BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38205199)

  • 1. Combinatorial therapy is a safe and durable treatment option in
    Jang C; Sabari J
    Transl Lung Cancer Res; 2023 Dec; 12(12):2558-2564. PubMed ID: 38205199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
    Katayama R; Friboulet L; Koike S; Lockerman EL; Khan TM; Gainor JF; Iafrate AJ; Takeuchi K; Taiji M; Okuno Y; Fujita N; Engelman JA; Shaw AT
    Clin Cancer Res; 2014 Nov; 20(22):5686-96. PubMed ID: 25228534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of
    Urbanska EM; Sørensen JB; Melchior LC; Costa JC; Santoni-Rugiu E
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325863
    [No Abstract]   [Full Text] [Related]  

  • 4. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
    Guo W; Liang J; Zhang D; Huang X; Lv Y
    Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of
    Makuuchi Y; Hayashi H; Haratani K; Tanizaki J; Tanaka K; Takeda M; Sakai K; Shimizu S; Ito A; Nishio K; Nakagawa K
    Oncotarget; 2018 May; 9(33):23315-23319. PubMed ID: 29796191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
    Peters S; Zimmermann S
    Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs.
    Leporati R; Miliziano D; Beninato T; Mazzeo L; Manglaviti S; Brambilla M; Occhipinti M; Prelaj A; Proto C; Lo Russo G
    Tumori; 2024 Apr; ():3008916241246659. PubMed ID: 38623748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
    Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
    Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome Inhibition Overcomes ALK-TKI Resistance in
    Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
    Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation of
    Xia G; Huang J; Ni J; Song M; Zhang J; Hofman P; Christopoulos P; Grenda A; Huang M
    Transl Lung Cancer Res; 2023 Mar; 12(3):637-646. PubMed ID: 37057117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.
    Arai S; Takeuchi S; Fukuda K; Taniguchi H; Nishiyama A; Tanimoto A; Satouchi M; Yamashita K; Ohtsubo K; Nanjo S; Kumagai T; Katayama R; Nishio M; Zheng MM; Wu YL; Nishihara H; Yamamoto T; Nakada M; Yano S
    J Thorac Oncol; 2020 May; 15(5):752-765. PubMed ID: 31972351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy.
    Vavalà T; Novello S
    Ther Adv Med Oncol; 2018; 10():1758835918789364. PubMed ID: 30090122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
    Isozaki H; Hotta K; Ichihara E; Takigawa N; Ohashi K; Kubo T; Ninomiya T; Ninomiya K; Oda N; Yoshioka H; Ichikawa H; Inoue M; Takata I; Shibayama T; Kuyama S; Sugimoto K; Harada D; Harita S; Sendo T; Tanimoto M; Kiura K
    Clin Lung Cancer; 2016 Nov; 17(6):602-605. PubMed ID: 27405684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report.
    Wang Z; Shi Y; Zhang P; Chen Y
    Chin Clin Oncol; 2023 Dec; 12(6):70. PubMed ID: 38195077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
    J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma.
    Pasau T; Wauters E; Wauters I; Duplaquet F; Pirard L; Pop-Stanciu C; D'Haene N; Dupont M; Vander Borght T; Rondelet B; Ocak S
    Front Oncol; 2022; 12():985446. PubMed ID: 36419902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: Durable response to alectinib in
    Rao C; Nie L; Wu X; Miao X; Chen T; Chen L; Zhang D; Lin Q
    Front Oncol; 2022; 12():915502. PubMed ID: 36203454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.